# Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

Study · id `cardio:ct-nct02556918` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02556918](<https://clinicaltrials.gov/study/NCT02556918>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02556918

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 202 participants.

## Technical summary

Registry record NCT02556918. Randomized; single masking; primary purpose prevention. Start 2016-01 (registry gives no type); primary completion 2018-11-06 (actual). Results posted on 2019-12-23.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 202 participants (enrolled count; ClinicalTrials.gov record NCT02556918, source copy `cardio:ctgov-nct02556918-2019-12-23`, retrieved 2026-10-26)
- Start date: 2016-01 (registry gives no type) (ClinicalTrials.gov record NCT02556918, source copy `cardio:ctgov-nct02556918-2019-12-23`, retrieved 2026-10-26)
- Primary completion: 2018-11-06 (actual) (ClinicalTrials.gov record NCT02556918, source copy `cardio:ctgov-nct02556918-2019-12-23`, retrieved 2026-10-26)
- Completion: 2018-11-06 (actual) (ClinicalTrials.gov record NCT02556918, source copy `cardio:ctgov-nct02556918-2019-12-23`, retrieved 2026-10-26)
- Results first posted: 2019-12-23 (ClinicalTrials.gov record NCT02556918, source copy `cardio:ctgov-nct02556918-2019-12-23`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02556918, source copy `cardio:ctgov-nct02556918-2019-12-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02556918-2019-12-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery
- Acronym: SITA-CABGDM
- Condition: Hyperglycemia
- Intervention (Drug): Sitagliptin
- Intervention (Drug): Placebo
- Intervention (Drug): Regular Human Insulin
- Intervention (Drug): Insulin glargine
- Intervention (Drug): Supplemental insulin (Insulin lispro)
- Intervention (Drug): Supplemental insulin (Insulin aspart)
- Lead sponsor: Emory University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Emory University (`cardio:org-emory-university`)

## Provenance

Content hash: 30c5c144179f1968dfcac1991fb3591a46b2d021d458c333357287dc80f5b369
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
